OvaScience, Inc. (OvaScience) is a global life sciences company. The Company is focused on the discovery, development and commercialization of new fertility treatments based on egg precursor or EggPC cells, which are immature egg cells found in the protective outer layer of a woman’s own ovaries. It offers AUGMENT Treatment. OvaScience’s treatment options under development include OvaPrime, OvaTure and OvaXon. With the AUGMENT treatment, energy-producing mitochondria from a patient’s own EggPC cells are added to the patient’s mature eggs during the IVF process to supplement the existing mitochondria. The AUGMENT treatment complements the standard of practice for an IVF cycle. OvaPrime treatment is a potential fertility treatment that could enable a woman to expand her egg reserve. OvaTure treatment is a potential next-generation IVF treatment that could help a woman produce healthy, young, fertilizable eggs without hormone injections.